Solving the Issue of Ionizing Radiation Induced Neurotoxicity by Using Novel Cell Models and State of the Art Accelerator Facilities

Celine Schielke¹, Carola Hartel¹, Marco Durante¹², Sylvia Ritter¹ and Insa S. Schroeder¹*

1 Biophysics Department, GSI Helmholtzzentrum für Schwerionenforschung, Darmstadt, Germany, ² Institut für Festkörperphysik, Technische Universität Darmstadt, Darmstadt, Germany

Cognitive dysfunction induced by ionizing radiation remains a major concern in radiation therapy as well as in space mission projects. Both fields require sophisticated approaches to improve protection of the brain and its neuronal circuits. Radiation therapy related research focusses on advanced techniques imposing maximal effect on the tumor while minimizing toxicity to the surrounding tissue. Research for example has led to the revival of spatially fractionated radiation therapy (SFRT) and the advent of FLASH radiotherapy. To investigate the influence of the space radiation environment on brain cells, low dose, high LET radiation in addition to simulated microgravity have to be studied. Both research areas, however, call for cutting-edge cellular systems that faithfully resemble the architecture of the human brain, its development and its regeneration to understand the mechanisms of radiation-induced neurotoxicity and their prevention. In this review, we discuss the proposed mechanisms of neurotoxicity such as the loss of complexity within the neuronal networks, vascular changes, or neuroinflammation. We compare the current in vivo and in vitro studies of neurotoxicity including animal models, animal and human neural stem cells, and neurosphere models. Particularly, we will address the new and promising technique of generating human brain organoids and their potential use in radiation biology.

Keywords: ionizing radiation, brain, neurotoxicity, X-rays, heavy ions, radiotherapy, space research, brain organoids

INTRODUCTION

Humans are unavoidably exposed to ionizing radiation (IR) from environmental and artificial sources [1]. The severity of radiation effects on the human organism depends on the dose and quality of radiation. High-LET (linear energy transfer) charged particles like carbon (\(^{12}\)C) ions lead, due to densely ionization events, to more severe damage compared to sparsely ionizing low-LET radiation, e.g., X- and \(\gamma\)-rays [2]. Regarding radiation impacts, the human brain is divided into different sub-structures at risk [3], but the effects of IR on the brain are still poorly understood. Thus, additional research is required in the fields of radiation therapy and space research for adapted risk assessment and for the development of adequate shielding methods [4, 5]. Cell [6] and animal models [7] provided first insights into the mechanisms underlying radiation-induced neurotoxicity such as impaired connectivity and neuronal function that govern
cognitive capabilities. However, these models lack the unique and complex architecture of the human brain, e.g., expanded neuronal cell diversity of millions of neurons organized in distinct functional regions, allowing higher cognitive abilities in humans [8]. So-called cerebral brain organoids exhibit several key features of the in vivo brain architecture and cell complexity and thus offer a more realistic microenvironment to investigate the impact of different noxae on the human brain [9]. This innovative model may improve our understanding of the mechanisms of radiation-induced late effects and enable the development of adequate countermeasures. Furthermore, brain organoids could be helpful to test the impact of novel irradiation modalities like SFRT and FLASH therapy before they are applied to the clinics.

NEUROTOXIC EFFECTS OF IONIZING RADIATION ON THE HUMAN BRAIN

The present knowledge of IR effects on the human brain is based primarily on data from epidemiological studies, particularly on Japanese atomic bomb survivors, as well as on cancer patients treated with radiotherapy. However, the affected persons were exposed at different ages and to different radiation qualities that influenced the varying outcomes of the radiation impacts [10, 11].

Epidemiological studies of prenatally exposed atomic-bomb survivors of Hiroshima and Nagasaki demonstrate that IR has, dependent on the dose and developmental stage, adverse effects on the developing brain. These manifest themselves in reduced head volumes in ∼42 % of the children irradiated in utero with doses from 0.5 to 0.99 Gy at gestational weeks 8–15 [12]. Additionally, exposure to 0.5–0.99 Gy negatively affected the neurocognition, shown in a decline in school performances in 38 % [13] and a reduction of 21–29 points in intelligence quotient (IQ)-tests per 1 Gy absorbed dose for individuals irradiated at gestational weeks 8–15 [14]. These studies demonstrate the harmful effects of IR on the developing brain, particularly at critical stages of neocortical development, such as gestational weeks 8–15. Furthermore, a cohort study of children that underwent conventional photon-radiotherapy with doses of 0.01–2.8 Gy during infancy (<18 months) due to cutaneous hemangioma, displayed cognitive impairments at the age of 18/19 years. These effects were noticeable as a decrease in high school attendance at doses greater than 0.1 Gy as well as a dose-response relation for cognitive performance measured by cognitive tests aimed at learning ability, and logical reasoning [15]. IR-induced long-term effects also have been reported for pediatric and adult patients with primary or metastatic brain tumors receiving 4–65 Gy cranial photon-radiotherapy [11]. Adverse effects become apparent ≥6 months after treatment and manifest themselves in progressive impairments, which are comparable with Alzheimer’s disease, such as deficits in memory, executive function, sustained attention, processing speed and learning, leading to a reduction of the patient’s quality of life [11, 16, 17]. Children are more strongly affected than adults due to the higher radio-sensitivities of the developing brain and a longer lifespan. It was shown that children that received 20–55 Gy of craniospinal photon radiotherapy due to central nervous system (CNS) malignancies at the age of ≤3 years displayed intellectual disability (Ø = −1.34 IQ-points per year) compared to non-irradiated children (Ø = + 0.91 IQ-points per year) [18]. This phenomenon was observable after the completion of therapy and during the follow-up time of ∼7.5 years. Also, photon irradiation of adult patients with primary, supratentorial brain tumors verifiably led to radiation-induced cognitive deficits, measured by worse results in experimental memory tests after fractionated radiotherapy with a total dose to the tumor of about 46–63 Gy [19]. Altogether, these studies confirm conventional treatment related impairments at any age of patients. Even though photon-based radiotherapy has been continually improved and still remains the standard modality for the treatment of brain tumors, particle-based radiotherapy that mostly relies on protons and carbon ions and enables a more efficient treatment of brain cancer patients, came into focus [20]. In contrast to photons, particle irradiation exhibits an advantageous dose distribution due to a unique absorption profile in the tissue with lower entrance doses and well-defined depth range with maximum dose deposition and increasing relative biological effectiveness (RBE) at the end of their range, called Bragg Peak. This depth-dose profile enables precise irradiation of deep-seated tumors while sparing the surrounding healthy tissue [21]. The use of protons and heavy ions to treat cancer was invented by researchers of the Lawrence Berkeley Laboratory, CA, USA in 1958 (Berkeley “synchrocyclotron”) [22]. However, it was first implemented clinically in Japan, in 1994, using the Heavy Ion Medical Accelerator in Chiba (HIMAC) [23]. In Europe, a patient pilot study (1997–2008) with 12C-ions at the Heavy Ion Synchrotron (SIS18) at GSI Helmholtz Center for Heavy Ion Research, Darmstadt (Germany), showed a promising outcome of tumor control and minimal toxicity for irradiation of skull base chordomas and chondrosarcomas [21, 24]. It led to the transfer of particle radiotherapy from physics laboratories to the Heidelberg Ion-Beam Therapy (HIT) Center that was opened in 2009. Due to a decreased neurotoxicity and increased success rate of particle therapy, the number of facilities and thus the number of patients treated with protons and 12C-ions steadily increased in recent years1. Meanwhile, 104 particle therapy facilities are in clinical operation worldwide2. For protons, reduced neurotoxic effect compared to photons was demonstrated by the studies of Kahalley et al. [25, 26]. Pediatric patients treated for brain tumors with protons showed less neuropsychological impairments in terms of intelligence, perceptual reasoning, processing speed, and working memory than those treated with X-rays [25, 26]. However, considering that continuously improved diagnostics and radiation treatments lead to an increased number of patients with longer lifespan and thus a higher risk for developing treatment-related late effects, the need for adequate model systems and suitable irradiation modalities arises.

---

1. https://www.ptcog.ch/index.php/ptcog-patient-statistics

2. https://www.ptcog.ch/index.php/facilities-in-operation
Cognitive deficits are also a major concern in long-term space mission beyond the shielding of the Earth's magnetosphere as reviewed by Cucinotta et al. [27]. Radiation-induced neurotoxicity is of particular interest, because the radiation environment in space differs significantly from the terrestrial. Terrestrial radiation exposure result mainly from radon-emitted, low energy alpha particles, and sparsely ionizing radiations, i.e., X-, β-, or γ-rays, while in deep space high-energy protons, helium, and heavier ions predominate. Therefore, space radiation induced biological damages can differ from those experienced on Earth. Moreover, effects of other spaceflight relevant factors, such as microgravity or disturbed circadian rhythm, may synergistically impair brain function. During long-term space missions the estimated total body equivalent dose for astronauts amounts to 1–2 mSv per day [28]. Potential CNS risks are reduced motor functions, neurocognitive deficits, probability of the occurrence of Alzheimer’s disease and premature aging [27]. As an example, a NASA study on identical twins indicates the potentially harmful effects of galactic cosmic radiation on the human brain. The space-twin, that participated in a one-year mission, demonstrated a post-flight decline in cognitive performance and speed, which persisted during the whole observation time of 6 months, compared to the twin that stayed on Earth [29]. These risks may compromise astronauts’ behavior under emergency conditions in deep space and justify the need of improved shielding methods. As the space radiation field and its effects are rather complex, it is difficult to predict the consequences for astronauts. Innovative accelerator facilities such as those available at FAIR/GSI can be used to simulate this mixed radiation field allowing a deeper insight into the CNS risk associated with cosmic radiation as well as the development of improved shielding methods. In summary, studying the effects of IR on the human brain is highly relevant, not only in context of risk assessment in radiotherapy, but also in terms of space research with a focus on shielding technologies.

Conventional Model Systems Used to Investigate IR-Induced Neurotoxic Effects

Because the molecular and cellular mechanisms underlying IR-induced neurocognitive deficits are still largely unknown, in vitro or in vivo models of the brain’s neurophysiology were developed to address this topic.

One of the earliest neuronal cell types are so-called neural stem cells (NSCs). These multipotent, dividing stem cells exist in the developing, embryonic brain as well as in the adult brain of mammalian organisms and represent the early precursors of the CNS-generating neurons and glia cells (astrocytes and oligodendrocytes) [30]. In rodents, two special niches of high-density cell division have been identified: the subventricular zone (SVZ) lining the lateral forebrain ventricles and the subgranular layer of the dentate gyrus (DG) in the hippocampus. In both sites of the rodent brain lifelong neurogenesis, i.e., differentiation of self-renewing NSCs into neurons and glia, takes place. These newly born neurons and glia cells then mature and migrate into the cortical, neuronal circuits to participate in cognitive functions like learning and memory [31, 32]. Whether and how adult human neurogenesis takes part, is highly debated and a challenging research topic [33, 34]. De novo formation of human neurons has been analyzed using doublecortin (DCX) or PSA-NCAM as markers for intermediate progenitor cells and early immature neurons (often dubbed “neuroblasts”). However, the source of these cells may not be embryonic-like NSCs but rather astrocytic cells [35]. Thus, human NSCs derived from embryonic/pluripotent stem cells may not reflect adult neurogenesis and its radiosensitivity, yet, they exhibit features of cancer stem cells [36] and therefore still contribute significantly to the radiation biology field. Consequently, mammalian NSCs were isolated from fetal or adult brain or differentiated from pluripotent stem cells, cultured as two-dimensional (2D) monolayers and used as in vitro models for radiation effects on neurogenesis [37]. Likewise, the more mature neurons can be isolated from human brain or can be differentiated in vitro from human NSCs. By applying various differentiation and growth factors, neurons of distinct subtypes including GABAergic, dopaminergic, and motor neurons were already generated and successfully used for studying neuronal functionality, synaptic plasticity, and injury [38]. However, these 2D-cell cultures do not consider the three-dimensionality of brain tissue. As a more realistic model system, neurospheres (NS), i.e., three-dimensional (3D) aggregates of several neural and neuronal progenitor types, derived from NSCs in suspension, were established. Within the NS, neural cells are able to self-renew, generate various neuronal and glial subtypes at different stages of maturation [39] and display neuronal function in the form of spontaneously generated action potentials [40]. An organ-like microenvironment with some degree of structural or organizational integrity can be achieved, as shown by Merz et al. [41], by culturing rodent and human tissue slices of about 300 μm at an air-liquid interface. These slices even display the tissues’ natural 3D-architecture up to 6 months. Finally, animal models, especially rodents, are used to investigate the radiation effects on the brain. The advantages of using animals as model organisms include, besides physiological similarity to humans, the entire vascularization and the complex biochemical and biomechanical microenvironment of the whole mammalian brain [7, 42].

IR-Induced Neurotoxic Effects

As seen from Table 1, several studies focused on the potential effects of sparsely IR on hippocampal neurogenesis. The observed radiation effects include a dose-dependent loss of NSCs [43, 44, 46, 47], a decreased proliferation rate of surviving NSCs [41, 43, 46–48, 53], impairments in the differentiation capability into neuronal and glial cells [44] and morphological changes in dendritic structure and neurite length [45, 50] leading to changes in synaptic transmission and therefore to a disturbed neuronal plasticity. Interestingly, these effects already occur at doses of about 1–2 Gy. This is of particular interest, because fractionated radiotherapy is usually performed with 1–3 Gy per fraction [68]. As seen from studies by Isono et al. [47], Morini et al. [48], and Yokota et al. [46], the effects on the NSCs were enhanced when irradiation was performed with particles, e.g., 12C-ions. These results verify the high radiation-sensitivity of non-differentiated neural stem and progenitor...
| Model                      | Irradiation                                                                 | Effects                                                                                                                                                                                                 | References |
|----------------------------|-----------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|
| Mouse NSCs                 | γ-rays 2 Gy in utero at E14.5 days of p21−/− and wt* mice                   | • Marked difference in the radiation response between lateral ganglionic eminences (LGE) and dorsal telencephalon  
• Particularly high apoptosis rate in SVZ cells of the LGE  
• Induction of G2/M and intra-S checkpoints within irradiated LGE, but no effect on the p21-dependent G1/S  
• Restoration of the pool of proliferating radial glia cells and massive cell death of intermediate progenitor cells 24 h post-IR | [43]      |
| Human NSCs                 | γ-rays 1, 2, 5 Gy                                                            | • Reduced differentiation potential even for 2 and 5 Gy  
• 1-5 Gy: reduced cell numbers by more than three-fold  
• G2/M arrest after 5 Gy  
• Rapid induction of apoptosis after 5 Gy  
• Dose-dependent increase in oxidative stress | [44]      |
| Human NSCs                 | γ-rays chronic exposure for 72 h with a total dose of 0.031, 0.124, 0.496 Gy | • Cell area and neurite length decrease in MAP2+ neural cells  
• Increased number of γ-H2AX nuclear foci  
• Altered gene expression profile at 72 h | [45]      |
| Human NSCs                 | γ-rays (0.2 keV/µm) 0.5, 1, 2, 4, 8 Gy 12C (108 keV/µm) 0.5, 1, 2, 4, 8 Gy | • Dose-dependent growth inhibition  
• Dose-dependent increased apoptosis  
• 12C-ions more effective than γ-rays | [46]      |
| Human NSCs                 | X-rays (150-kVp, ~1 Gy/min) 2–10 Gy 12C (290 MeV/u, SOBP*, average LET 50 keV/µm) 2–10 Gy | • Decreased growth rate  
• IR induced dose-dependent apoptosis in both cases (~90%), rarely necrosis  
• 12C-ions more effective than X-rays | [47]      |
| Human NSCs                 | X-rays 2–20 Gy 12C (SOBP, 246-312 MeV/u, LET 86.6–97.8 keV/µm) 5–20 Gy | • ≥10 Gy: Reduction in viability up to 56% 48 h post-IR, stronger effect 7 days post-IR  
• 48h post-IR: no strong statistically significant effect  
• 7 days post-IR: reduction in viability up to 62 % | [48]      |
| Mouse NS                   | 56Fe (600 MeV/u, fluence: 500–30,000 pa/cm²) 0–8 Gy                       | • Dose-dependent reduced cell survival  
• Neurosphere cultures contain populations of cells with different sensitivities to irradiation  
• Exposure to IR lead to dose-dependent rise in oxidative stress | [49]      |
| Neurons from E18 rat       | γ-rays 10 Gy                                                                | • Initial increase in spines and excitatory synapses followed by decrease in spine/synapse density with altered spine dynamics  
• changes in synaptic structural plasticity | [50]      |
| hippocampi after 21 days in culture |                                                                                |                                                                                                                                     |            |
| Archival and autopsy human hippocampal tissue | 13.2–36 Gy total body IR or craniospinal with/without boost to the posterior fossa | • 10- to 100-fold (child) reduction of hippocampal neurogenesis (decreased generation of early DCX+ neurons)  
• radiation-induced inflammation (two-fold more activated microglia) | [51]      |
| Mouse hippocampal slices  | X-rays 7, 30 Gy                                                              | • Decreased cell number  
• Morphological changes  
• Increase in migration velocity of microglia | [52]      |
| Human brain tumor slices  | X-rays 4 Gy                                                                 | • 40 Gy blocked the normal proliferation  
• Dose-dependent DNA damage (double-strand breaks) | [41]      |
| Human brain tumor slices  | X-rays 4 Gy                                                                 | • ~ 50% inhibition of proliferation after 24 h  
• Increase in cell death  
• ~ 40% inhibition of proliferation after 24 h, massive DNA-damage  
• Increase in cell death after 2 Gy | [53]      |
| Rhesus macaques            | γ-rays 6.75–8.06 Gy whole body                                                | • IR led to worse long-term results in visual discrimination tests suggesting relative deficiency in cognitive flexibility | [54]      |
### TABLE 1 | Continued

| Model  | Irradiation | Effects | References |
|--------|-------------|---------|------------|
| Mouse  | X-rays 10 Gy bilateral hippocampus/cortex | • Hippocampal-dependent spatial learning and memory impairments in the Barnes maze <br>• Reduction of hippocampal neurogenesis (reductions in proliferation and DCX+ neurons in the SGZ) | [55] |
| Rat    | X-rays 2, 10 Gy brain | • Dose-dependent inhibition of neural precursor cell proliferation in the hippocampus <br>• Depletion of neural progenitor cells exposed to 10 Gy <br>• 97% reduction in newborn neurons <br>• No adverse effect on astrocytes or oligodendrocytes <br>• Neuroinflammation (increase activated microglia) | [56] |
| Mouse  | X-rays 2, 5, 10 Gy brain | • Dose-dependent increased apoptosis <br>• Proliferating cells in SGZ reduced by 93–96% <br>• Dose-dependent decrease of immature neurons up to 40–60%  <br>• No effect on astrocytes or oligodendrocytes <br>• Neuroinflammation (increase activated microglia) | [57] |
| Rat    | X-rays 6 Gy whole brain IR | • Long-term suppression of neurogenesis in olfactory bulb and dentate gyrus <br>• No long-term reduction of progenitor cells in SVZ, but marked decrease in dentate gyrus <br>• Only acute, but not persistent activation of microglia | [58] |
| Rat    | X-rays 25 Gy brain | • Suppression of SVZ proliferation in neuroblasts and interneurons, recovery in the olfactory bulb <br>• Limited proliferation of oligodendrocyte precursors (O-A2) followed by demyelination <br>• Restoration of endothelium <br>• White matter necrosis <br>• Early loss of young oligodendrocyte progenitors and delayed loss of more mature oligodendrocytes lineage cells in human tissue | [59] |
| Rat    | X-rays 8, 10, 13 Gy brain | • > 10 Gy: Hippocampal spatial memory impairment evaluated by Barnes maze <br>• > 0.2 Gy Hippocampal spatial memory impairment (Barnes maze test) | [60] |
| Rat    | 56Fe (1 GeV/u) 1.5 Gy whole body IR | • Impaired spatial learning and memory tested in Morris water maze | [61] |
| Rat    | 56Fe (1 GeV/u) 1.5 Gy brain | • Increase in reference memory errors negatively correlated with proteins expression that play roles in cognition (PRKA, synaptophysin, DCF of the striatum and synaptophysin of the frontal cortex) | [62] |
| Mouse  | 56Fe (600 MeV/u, LET 175.2 keV/µm at the target surface) 0.5–4 Gy brain | • Dose-related decrease in hippocampal neurogenesis <br>• Neuroinflammation (increase in numbers of newly born activated microglia) | [63] |
| Rat    | 56Fe (1 GeV/u) 0.02 Gy brain | • Significant impairments in learning and memory tested by the attentional set-shifting test | [64] |
| Mouse  | 56Fe (600 MeV/u) 0.1, 0.2, 0.5 Gy whole body IR | • Cognitive impairment in novel object recognition tested in Morris water maze <br>• Cognitive effects not induced by oxidative damage | [65] |
| Mouse  | Protons (1GeV/u) 0–0.2 Gy whole body IR | • ≥ 0.1 Gy decreased hippocampal cell proliferation <br>• ≥ 0.5 Gy decreased neurogenesis <br>• No astrocyte or microglia activation | [66] |
| Mouse  | Protons (250 MeV/u) 0.1, 1 Gy whole body IR | • Dose-dependent reductions in dendritic complexity (~33 %) and spine density (50–75 %) along hippocampal neurons <br>• Dose-responsive reductions in neurons’ synaptophysin expression | [67] |

The table shows the dose range applied in the respective study. Endpoints may have been obtained using smaller dose ranges or single doses; energies and doses are indicated when provided by the authors.

*wt, wildtype; SOBP, Spread-Out Bragg Peak; 12C, carbon; 56Fe, iron; pa, particles.
cells and correlate with the radiation-sensitive stage of early embryonic neurogenesis. Despite differences in neurogenesis between humans and rodents, as discussed above, there are some similarities in the radiation response, e.g., activation of microglia [51, 52, 56, 58]. Astrocyte and endothelium mediated secondary vascular abnormalities and the subsequent disruption of the blood brain barrier cause this activation of microglia, the phagocytic cells of the CNS. This induces chronic neuroinflammation via the release of pro-inflammatory cytokines, which also leads to degenerative changes in the white matter [51, 56, 57, 69]. In vitro and in vivo studies have shown that IR can further lead to an increase of oxidative stress producing DNA-damage and causes apoptotic cell death in neuronal, glial, and endothelial cell types in NSCs and NS [44, 49] as well as in rats [59]. In rodents, the radiation-induced loss of glial oligodendrocyte progenitor cells followed by demyelination of neurons ends up with white matter necrosis [59], which is also seen in humans [70]. These impacts on mammalian brains may contribute to impairments in behavior and to memory deficits as assessed by the Barnes maze [55, 60] and visual discrimination tests [54] and may also mirror cognitive defects seen in humans.

Studies analyzing the effects of space-relevant $^{56}$Fe-ions on rodents (see Table 1) have shown that doses < 1 Gy impair neurogenesis as well as neuronal function [62, 63] and can cause cognitive deficits. The irradiated animals exhibit persistent hippocampal and cortical based performance decrements in memory and behavioral tests [60, 61, 64, 65]. Comparative studies demonstrated that even exposure to 0.2 Gy $^{56}$Fe (1 GeV/u) resulted in cognitive impairments whereas X-ray exposure did not result in memory deficits until doses > 10 Gy indicating a high effectiveness of Fe (estimated RBE ~ 50) [60]. Additionally, mice that were exposed to protons with doses as low as 0.1–0.5 Gy also showed a decreased hippocampal cell proliferation and deficits in neurogenesis and synaptic plasticity [66]. These findings demonstrate the stronger effect of particle irradiation compared to photons and strengthen concerns about potential cognitive changes after space mission. However, the animal studies have been performed predominantly with $^{56}$Fe-ions and therefore do not represent the full complexity of the space radiation environment, nor the continuous irradiation over several weeks and months in space.

In summary, these findings demonstrate the complex and dynamic effects of radiation on multiple cell types of the brain, including NSCs, oligodendrocytes, astrocytes, microglia, and neurons as well as vascular endothelial cells (Figure 1). Furthermore, comparative studies demonstrated the greater effectiveness of space relevant $^{58}$Fe-ions on CNS cells in comparison to photons. These radiation mediated impacts may contribute to diverse brain damages and neurodegenerative diseases, even though the detailed mechanisms of cognitive impairments remain largely unknown.

**Limitations of Conventional Model Systems**

The model systems listed above, particularly the in vitro ones, have disadvantages. Despite the progress that has been made in understanding the hallmarks of brain development and neurogenesis as well as in investigating the neurotoxicity of IR using of 2D-cell cultures, these cell systems display distinct differences in morphology, metabolism, and differentiation compared to the in vivo situation [6]. Specifically, the NSC monolayer system only allows investigating IR effects on the very early and primitive neurogenesis as discussed above. Therefore, they neither address processes in the adult brain nor are they capable of reflecting the complex cell-layering and diversity seen in the human brain’s architecture. The same applies to neurons cultivated in vitro as monolayers. In contrast, 3D-neurophores contain cells at multiple stages of differentiation but lack cell-organization and hierarchical complexity found in the human brain in vivo [71]. A more relevant model is presented by human brain slice cultures from postmortem tissue or resected tissue from operations [72]. In vitro, their morphology and physiological characteristics can be partly preserved for up to 50 days [73]. However, there are striking differences between postmortem and resected slices in the processing of slices and transfer to the in vitro conditions, neuronal survival has to be sustained by elaborate culture conditions and finally procurement of human brain slices is challenging and impedes larger studies. In radiation biology, rodent studies are frequently used allowing first insights into the molecular mechanisms underlying cognitive dysfunction. However, apart from the ethical discussions on the use of animals in research, mice, and humans display species-specific differences, that speak against the use of animals as a model [42]. In addition to obvious differences in brain size and architecture due to the folding of the human brain, particularly the existence of neural stem cells, called outer radial glia, residing in the outer subventricular zone, and a greater diversity in neuronal cell types [74–76] sets the human brain apart from other mammalian ones. Notably, even between homologous human and mouse cell types, single-nucleus RNA-sequencing analyses verified significant differences in gene expression [8]. All these main features of the human brain allow for higher cognitive functions, but also justify the need for a more adapted and adequate brain model to investigate the molecular and functional effects of radiation in various brain regions and cell types. Some of the disadvantages of the discussed models can be overcome by human brain organoids that will be discussed in the following chapter.

**ORGANOID AS NOVEL **IN VITRO** TOOL FOR THE HUMAN BRAIN**

In recent years, so-called brain or cerebral organoids, differentiated from human embryonic stem cells (hESCs) or patient-relevant induced pluripotent stem cells (iPSCs), came into focus as a novel in vitro tool in regenerative medicine/disease modeling [77], whereas the potential for radiation biology is not yet exploited. Organoids are 3D spontaneously self-organized, organ-like structures that are able to develop into various interdependent brain regions containing different organ-specific cell types arranged in distinct layers (Figure 2). In contrast to rodent models, these organoids exhibit several key features of
the human in vivo brain organogenesis like an independent progenitor layer with the unique neural stem cells called outer radial glia. In addition, it has already been reported that animal models failed to recapitulate the symptoms of human neurological diseases, such as micro- and macrocephaly while human organoids have this ability. Therefore, they provide a novel predictive preclinical tool to investigate the detailed molecular mechanisms underlying congenital, cognitive diseases and the effects of potential neuro-therapeutics in functional human tissues [78]. Brain organoids thus provide the opportunity to model unique features of early human brain development, as well as human neurogenesis and neuro-regeneration [9, 79], and may allow a better understanding of the mechanisms underlying ionizing radiation-induced cognitive impairments and disease.

Mimicking in vivo patterning by supplementing external patterning factors, organoids of diverse functional brain regions, including organoids of the ventral forebrain [80, 81], midbrain [82, 83], hypothalamus [84], cerebellum [85], and pituitary [86] were generated in suspension. Culture conditions were improved by using spinning reactors and orbital shakers at moderate throw and speed, which provide enhanced nutrient and oxygen supply and culture time without causing adverse shear stress. Such sustained suspension culture leads to an enhanced differentiation process of neurons compared to those derived in 2D-monolayers and the formation of active neuronal networks [84, 87–89]. In addition, different region-specific spheroids, such as cortical spheroids of the dorsal and ventral forebrain, can be fused to generate so-called “assembloids” (Figure 3). Consequently, migration of interneurons and the interactions between different brain regions or different cell types can be tracked [90–93]. Other studies demonstrated the incorporation of microglia as the brains innate immune cells into the organoid-model [94, 95]. This allows investigating the effects of combined therapies, e.g., radio- and immunotherapy, on the human CNS. Another approach is the generation of brain tumors in normal organoids as a realistic microenvironment [96] that will permit a better understanding of tumor and normal tissue interaction in response to IR. Yet, radiobiological studies using brain organoids have not been published. However, brain organoids were recently implemented in ground-based experiments investigating the effects of microgravity on neural progenitor cell fate [97]. They showed an altered gene expression of rostral-caudal and cortical markers that may influence brain structure and physiology, indicating the usability of brain organoids in space radiation research to identify the mechanisms affecting brain function and, e.g., in the development of new shielding methods to protect the brain’s neuronal circuits. In our own studies, we were able to reproducibly show radiation impacts such as apoptosis and necrosis changing the structure and composition of cerebral organoids (unpublished data).

But even if organoids currently are viewed as state-of-the-art in vitro models of the human brain, there are still challenges to be overcome. Because of the lack of endothelial cells and thus vascularization, organoids will develop a necrotic core and terminal maturation and differentiation is limited. Therefore, Giandomenico et al. [98] chose an alternative approach for an improved oxygen supply cultivating organoid slices at an air-liquid interface. These organoid slices demonstrated an increased...
FIGURE 2 | Immunocytochemical staining of a cerebral organoid slice showing human brain-like hierarchical organization with the radial glia marker PAX6 (Paired box 6, red) in the inner ventricular layer of the brain lobes. Nuclei stained with Hoechst 33342 (blue). Scale bar: 200 µm.

FIGURE 3 | Pluripotent, embryonic stem cell (ESCs)-based 2D-, 3D cell- and organoid systems as in vitro tools for studying the effects of ionizing radiation on the human brain.

Survival rate and an extensive axon outgrowth reminiscent of nerve tracts. Another issue is the lack or scarcity of glial cell populations. A new differentiation approach uses more complex differentiation factors to generate mature oligodendrocytes in brain organoids [99]. Nevertheless, the batch variations and thus heterogeneity of the generated organoids still poses a problem for statistically significant and expressive results, although there are new methods for generating more homogeneous organoids by using microfilaments as floating scaffolds [100]. Despite these improvements, it is technically very challenging to
obtain homogeneous batches and the organoids show statistical
variations also seen in animal experiments; therefore, more
sophisticated bioengineering techniques are presently explored.
One approach is the use of 3D bio printing technologies to
produce consistent scaffolds as a basis of organoid formation.
A further challenge is the adaptation of standardized analytical
protocols such as immunohistochemical staining procedures to 3D-
organoids. In the same line, single-cell mRNA sequencing
[88] techniques have been proven more meaningful than
standard polymerase chain reactions (PCR). Despite these
challenges, brain organoids represent a versatile model system
allowing a variety of studies that will improve the understanding
of radiation impacts on the human brain at any stage of
development and regeneration.

IMPROVING PARTICLE THERAPY AND
RADIATION RISK ASSESSMENT USING
BRAIN ORGANOIDS AT STATE OF THE ART
ACCELERATOR FACILITIES

New accelerators such as the Facility for Antiproton and Ion
Research (FAIR) in Darmstadt, Germany, that is to be completed
in 2025, can produce heavy ion beams up to around 10 GeV/n
as compared to 1 GeV/n with the current setting (reviewed in
[101]). This is particularly relevant for ground-based studies
of possible galactic cosmic radiation (GCR) effects, as part of
the particle flux in the GCR exceeds 1 GeV/n [102]. However,
very few studies to date have addressed high-energy ranges > 1
GeV/n. Meaningful risk assessment specifically of interplanetary
missions therefore will rely on those state of the art accelerator
facilities and brain organoids can serve as a high throughput
biological risk model. While astronauts are subject to chronic
irradiation, accelerator-based experiments normally use acute
dose exposure due to beamtime constraints, even though long-term
experiments are technically feasible. High beam intensities,
delivered by facilities like FAIR, are also of interest for the
use of ultra-high dose rate (FLASH) radiotherapy with protons
or potentially heavy ions such as carbon. This experimental
radiation modality can reduce neurotoxic effects in the healthy
tissue by increasing the dose rate to ≥40 Gy/s. Even though
detailed mechanisms underlying the greater radioresistance
are still unknown, acute oxygen depletion within the irradiated
tissue or chromatin remodeling is discussed as possible cause for
the increased effectiveness [103]. Here again, organoids serve as
ideal models due to their innate oxygen gradient within their
various layers from the hypoxic core to the normoxic outer
layer of the cortical plate. An initial study of a first patient
with subcutaneous T-cell lymphoma confirmed the benefits of
FLASH radiation by demonstrating a complete response of the
tumor and minimal normal tissue toxicities [104]. However, the
remaining studies focus mainly on animal models, e.g. Montay-
Gruel et al. [205] demonstrated that spatial memory of mice is
preserved after 10 Gy FLASH-whole-brain irradiation with
mean dose rates above 100 Gy/s, whereas 10 Gy whole-brain
irradiation at a conventional dose rate (0.1 Gy/s) impairs spatial
memory [105]. Due to the limited number of suitable accelerator
facilities providing the necessary technology to perform FLASH
irradiations [106] and the lack of suitable human biological
models, studies regarding FLASH radiotherapy are rare and
transformation to the clinics remains a challenge. High throughput,
organoid based studies could shed light on the molecular
mechanisms of the observed effects, particularly the contribution
of hypoxia, and overcome these challenges.

Of particular interest in radiation therapy is also the use of
ions other than protons and carbon. Helium ions for instance
are discussed to be more suitable than protons due to an
improved RBE in the Bragg-Peak region and an improved
oxygen enhancement ratio [107] and therefore may be especially
beneficial for pediatric patients [108] in terms of long-term side
effects particularly to the brain. Research accelerator facilities
offer the possibility to test these rarely used ions and mixed ion
modalities (proton, helium, oxygen, carbon) on their neurotoxic
behavior and to ensure risk-free implementation into the clinics.

Another approach to improve radiotherapy outcome is
the so-called spatially fractionated radiotherapy (SFRT), the
inhomogeneous irradiation with a stack or grid of small radiation
beams. Depending on the beam spot size, these are known as
spatially fractionated mini- or microbeam SFRT. Photon
SFRT with a spot size in the mm range was first introduced
more than a century ago to reduce skin necrosis and is used
clinically (in combination with conventional radiotherapy) for
many years [109]. In contrast, microbeam SFRT is still in a
pre-clinical stage. In animal models, extremely high doses of
hundreds of Gy delivered by microbeam photon SFRT were
tolerated well e.g., by rat brain [110] and spinal cord [111],
raising hopes that spatially fractionated radiotherapy allows dose
escalation and thus improved tumor control without severe
normal tissue complications. Compared to photon SFRT, SFRT
with protons, and potentially heavier accelerated ions, combines
the advantages of SFRT and particle therapy (reviewed in [112])
and is well tolerated by brain tissue in a rat animal model [113].
Recent clinical proof-of-concept studies and constant technical
improvements enable the transition of proton SFRT to clinical
application [114–116]. Photon SFRT and especially proton or
heavy ion SFRT have great therapeutic potential, allowing tumor
dose escalation with good normal tissue tolerance. However, the
biological mechanisms behind SFRT are not fully understood.
In this rapidly developing field, human brain organoids, combining
the advantages of a human brain architecture and a reliable in vitro
system, can be a useful tool both in the exploration of new
SFRT techniques as well as in the discovery of the biological
mechanisms underlying SFRT.

CONCLUSION

Despite remaining challenges, brain organoids present the
most realistic human in vitro brain model so far and have
everous potential to pave the way for new research findings
in the field of radiation research. These model systems will
allow meaningful research and improvements in the fields of
cancer therapy (acute high dose exposure) and space radiation
(chronic low dose exposure) protection while partly replacing
and streamlining time-consuming and ethically controversial animal studies. Furthermore, in contrast to the clinical facilities, new research facilities such as FAIR offer the implementation of varying and more complex experimental designs due to more flexible changes in irradiation conditions. Combining both, state of the art biological models and state of the art accelerators will enable us to address issues in radiation biology in an unprecedented fashion.

**AUTHOR CONTRIBUTIONS**

CS: data acquisition and manuscript writing. CH, SR, and IS: data acquisition, manuscript writing, and review. MD: manuscript review. All authors contributed to the article and approved the submitted version.

**FUNDING**

This work was funded by the Bundesministerium für Bildung und Forschung (BMBF) within the Brain Radiation Assay project (02NUK049A).

**ACKNOWLEDGMENTS**

The authors thank all the members of the working group for their valuable comments, helpful critiques, and discussions.

**REFERENCES**

1. United Nations Scientific Committee on the Effects of Atomic Radiation. *Sources and Effects of Ionizing Radiation*. 1st ed. New York, NY: United Nations; 2010

2. Krämer M, Kraft G. Track structure and DNA damage. *Adv. Space Res.* (1994) 14:151–9. doi: 10.1016/0273-1177(94)90465-0

3. Scoccianti S, Detti R, Gadda D, Greto D, Furfaro I, Meacci F, et al. Organs at risk in the brain and their dose-constraints in adults and in children: a radiation oncologist’s guide for delineation in everyday practice. *Radiother Oncol.* (2015) 114:230–8. doi: 10.1016/j.radonc.2015.01.016

4. Sousassin C, Ricard D, Fike JR, Mazeron J-J, Pismararas D, Delattre J-Y. CNS complications of radiotherapy and chemotherapy. *Lancet.* (2009) 374:1639–51. doi: 10.1016/S0140-6736(09)61299-X

5. Durante M, Cucinotta FA. Physical basis of radiation protection in space travel. *Rev. Mod. Phys.* (2011) 83:1245–81. doi: 10.1103/RevModPhys.83.1245

6. Duval K, Grover H, Han I-H, Mou Y, Pogoraro AF, Fredberg J, Chen Z. Modeling physiological events in 2D vs. 3D cell culture. *Physiology (Bethesda).* (2017) 32:266–77. doi: 10.1152/physiol.00036.2016

7. Verhaegen F, Granton P, Tryggstad E. Small animal radiotherapy research platforms. *Phys. Med. Biol.* (2011) 56:R853–83. doi: 10.1088/0031-9155/56/12/R01

8. Hodge RB, Bakken TE, Miller JA, Smith KA, Barkan ER, Graybucket LT, et al. Conserved cell types with divergent features in human versus mouse cortex. *Nature.* (2019) 573:61–8. doi: 10.1038/s41586-019-1506-7

9. Lancaster MA, Remmer M, Martin C-A, Wenzel D, Bicknell LS, Hurles ME, et al. Cerebral organoids model human brain development and microcephaly. *Nature.* (2013) 501:373–9. doi: 10.1038/nature12517

10. Hladik D, Tapio S. Effects of ionizing radiation on the mammalian brain. *Mutat. Res.* (2016) 770:219–30. doi: 10.1016/j.mrrev.2016.08.003

11. Crossen JR, Garwood D, Glatstein E, Neuweiler EA. Neurobehavioral sequelae of cranial irradiation in adults: a review of radiation-induced encephalopathy. *J Clin Oncol.* (1994) 12:627–42. doi: 10.1200/JCO.1994.12.3.627

12. Otake M, Schull WJ. Radiation-related small head sizes among prenatally exposed A-bomb survivors. *Int J Radiat Biol.* (1993) 63:255–70. doi: 10.1080/09553009314550341

13. Yoshimaru H, Otake M, Fujikoshi Y, Schull WJ. Effect on school performance of prenatal exposure to the Hiroshima atomic bomb. *Nihon Iseigaku Zasshi.* (1991) 46:47–54. doi: 10.1265/j.1467.4747

14. Schull WJ, Otake M, Yoshimaru H. Effect on Intelligence Test Score of Prenatal Exposure to Ionizing Radiation in Hiroshima and Nagasaki. Hiroshima: Radiation Effects Research Foundation (1988).

15. Hall P, Adami H-O, Trichopoulos D, Pedersen NL, Lagiou P, Ekbom A, et al. Effect of low doses of ionising radiation in infancy on cognitive function in adulthood. Swedish population based cohort study. *BMJ.* (2004) 328:19. doi: 10.1136/bmj.328.7430.19

16. Meyers CA, Brown PD. Role and relevance of neurocognitive assessment in clinical trials of patients with CNS tumors. *J Clin Oncol.* (2006) 24:1305–9. doi: 10.1200/JCO.2005.04.6086

17. Roddy E, Mueller S. Late effects of treatment of pediatric central nervous system tumors. *J Child Neurol.* (2016) 31:237–54. doi: 10.1177/1087413515587944

18. Fouladi M, Gilger E, Kocak M, Wallace D, Buchanan G, Reeves C, et al. Intellectual and functional outcome of children 3 years old or younger who have CNS malignancies. *J Clin Oncol.* (2005) 23:7152–60. doi: 10.1200/JCO.2005.01.214

19. Armstrong CL, Shera DM, Lustig RA, Phillips PC. Phase measurement of cognitive impairment specific to radiotherapy. *Int J Radiat Oncol Biol Phys.* (2012) 83:e319–24. doi: 10.1016/j.ijrobp.2011.12.083

20. Durante M, Loeffler JS. Charged particles in radiation oncology. *Nat Rev Clin Oncol.* (2010) 7:37–43. doi: 10.1038/nrclinonc.2009.183

21. Kraft G. Tumor therapy with heavy charged particles. *Prog. Particle Nucl Phys.* (1958) 18:121–34

22. Lawrence JH, Tobias CA, Born JL, Mccombs RK, Roberts JE, Anger HO, et al. Pituitary irradiation with high-energy proton beams: a preliminary report. *Cancer Res.* (1958) 51:61–8. doi: 10.1177/0008547215587944

23. Kitagawa A, Fujita T, Muramatsu M, Biri S, Drentje AG. Review on heavy ion radiotherapy facilities and related ion sources (invited). *Rev Sci Instrum.* (2010) 81:02B909. doi: 10.1063/1.3268510

24. Schulte-Ernter D, Nikoghosyan A, Thilmann C, Haberer T, Jäkel O, Karger C, et al. Results of carbon ion radiotherapy in 152 patients. *Int J Radiat Oncol Biol Phys.* (2004) 58:631–40. doi: 10.1016/j.ijrobp.2003.09.041

25. Kahalley LS, Peterson R, Ris MD, Janzen L, Okcu MF, Grosshans DR, et al. Superior intellectual outcomes after proton radiotherapy compared with photon radiotherapy for pediatric medulloblastoma. *J Clin Oncol.* (2020) 38:454–61. doi: 10.1200/JCO.20.191706

26. Kahalley LS, Ris MD, Grosshans DR, Okcu MF, Paulino AC, Chintagumpala M, et al. Comparing intelligence quotients after treatment with proton versus photon radiotherapy for pediatric brain tumors. *J Clin Oncol.* (2016) 34:1043–9. doi: 10.1200/JCO.2015.62.1383

27. Cucinotta FA, Alp M, Sulzman FM, Wang M. Space radiation risks to the central nervous system. *Life Sci Space Res.* (2014) 2:54–69. doi: 10.1016/j.lssr.2014.06.003

28. Cucinotta FA, Durante M. Cancer risk from exposure to galactic cosmic rays: implications for space exploration by human beings. *Lancet Oncol.* (2006) 7:431–5. doi: 10.1016/S1470-2045(06)70695-7

29. Garrett-Bakelman FE, Darshi M, Green SJ, Gur RC, Lin L, Macias BR, et al. The NASA Twins Study: A multidimensional analysis of a year-long human spaceflight. *Science.* (2019) 364:eaau8650. doi: 10.1126/science.aau8650

30. Götz M, Nakafuku M, Petrik D. Neurogenesis in the developing and adult brain-similarities and key differences. *Cold Spring Harb Perspect Biol.* (2016) 8:a018853. doi: 10.1101/cshperspect.a018853

31. Doetsch F, Caillé I, Lim DA, García-Verdugo JM, Alvarez-Buylla A. Subventricular zone astrocytes are neural stem cells in the adult mammalian brain. *Cell.* (1999) 97:763–16. doi: 10.1016/S0092-8674(98)00783-7
32. Palmer TD, Takahashi J, Gage FH. The adult rat hippocampus contains primordial neural stem cells. Mol Cell Neurosci. (1997) 8:389–404. doi: 10.1006/mcne.1996.0595
33. Bergmann O, Spalding KL, Frisén J. Adult neurogenesis in humans. Cold Spring Harb Perspect Biol. (2015) 7:a018994. doi: 10.1101/cshperspect.a018994
34. Kempermann G, Gage FH, Aigner L, Song H, Curtis MA, Thuret S, et al. Human adult neurogenesis: evidence and remaining questions. Cell Stem Cell. (2018) 23:25–30. doi: 10.1016/j.stem.2018.04.004
35. Magnusson JP, Frisén J. Stars from the darkest night: unlocking the extracellular matrix niche microenvironment of neural and cancer stem cells in the brain. Int J Biochem Cell Biol. (2016) 81:174–83. doi: 10.1016/j.biocel.2016.05.002
36. Reinhard J, Brösicke N, Theocharidis U, Faissner A. The extra cellular matrix contains primordial neural stem cells. Stem Cells. (2000) 187:1433–8. doi: 10.1121/science.287.5457.1433
37. Hanbury DB, Peiffer AM, Dugan G, Andrews RN, Cline JM. Long-term cognitive functioning in single-dose total-body gamma-irradiated rhesus monkeys (Macaca mulatta). Radiat Res. (2016) 186:447–54. doi: 10.1667/RR14430.1
38. Raber J, Rola R, LeFever A, Morhardt D, Carley J, Mizumatsu S, et al. Radiation-induced cognitive impairments are associated with changes in indicators of hippocampal neurogenesis. Radiat Res. (2004) 162:39–47. doi: 10.1667/RR3206
39. Monje ML, Mizumatsu S, Fike JR, Palmer TD. Irradiation induces neural precursor-cell dysfunction. Nat Med. (2002) 8:955–62. doi: 10.1038/nm749
40. Monje ML, Mizumatsu S, Fike JR, Palmer TD, Rola R. Extreme sensitivity of adult neurogenesis to low doses of X-irradiation. Cancer Res. (2003) 63:4021–7.
41. Perlman RL. Mouse models of human disease: An evolutionary perspective. Biosens Bioelectron. (2010) 25:462–8. doi: 10.1016/j.bios.2010.06.003
42. Merz F, Müller M, Taucher-Scholz G, Rödel F, Stöcker H, Schopow K, et al. Effects of chronic low-dose radiation on neural progenitor cells. Stem Cells Transl Med. (2016) 5:289–94. doi: 10.1002/stem.11709
43. Repp RJ, Wijesinghe JS, Olson RHJ, Davis MJ, Johnson LA, Raber J. Early effects of whole-body (56)Fe irradiation on hippocampal function in C57BL/6J mice. Radiat Res. (2011) 178:289–94. doi: 10.1667/RR2862.1
44. Katsura M, Cyou-Nakamine H, Zen Q, Zen Y, Nansai H, Amagasa S, et al. Neuroprotective effects of Ringer saline on ischemic brain injury. Brain Res. (2010) 1280:172–8. doi: 10.1016/j.brainres.2010.06.021
45. Hanbury DB, Peiffer AM, Dugan G, Andrews RN, Cline JM. Long-term cognitive functioning in single-dose total-body gamma-irradiated rhesus monkeys (Macaca mulatta). Radiat Res. (2016) 186:447–54. doi: 10.1667/RR14430.1
46. Raber J, Rola R, LeFever A, Morhardt D, Carley J, Mizumatsu S, et al. Radiation-induced cognitive impairments are associated with changes in indicators of hippocampal neurogenesis. Radiat Res. (2004) 162:39–47. doi: 10.1667/RR3206
47. Isono M, Yoshida Y, Funayama T. Distinct modes of death at hippocampal excitatory synapses. Neuron. (2018) 98:694–702. doi: 10.1016/j.neuron.2018.11.003
48. Monje ML, Mizumatsu S, Fike JR, Palmer TD. Irradiation induces neural precursor-cell dysfunction. Nat Med. (2002) 8:955–62. doi: 10.1038/nm749
49. Monje ML, Mizumatsu S, Fike JR, Palmer TD. Extreme sensitivity of adult neurogenesis to low doses of X-irradiation. Cancer Res. (2003) 63:4021–7.
40. Monje ML, Mizumatsu S, Fike JR, Palmer TD, Rola R. Extreme sensitivity of adult neurogenesis to low doses of X-irradiation. Cancer Res. (2003) 63:4021–7.
disorders and potential therapeutic compounds. *Neurosci Bull.* (2019) 35:244–52. doi: 10.1007/s11264-018-0328-1

73. Verwer RWH, Hermens WJTMC, Dijkstra-P, ter Brake O, Baker RE, Salehi A, et al. Cells in human postmortem brain tissue slices remain alive for several weeks in culture. *FASEB J.* (2002) 16:54–60. doi: 10.1096/fasebj.16.1.01-5094

74. Lui JH, Hansen DV, Kriegstein AR. Development and evolution of the human neocortex. *Cell.* (2011) 146:18–36. doi: 10.1016/j.cell.2011.06.030

75. Fish JL, Dehay C, Kennedy H, Huttner WB. Making bigger brains—the evolution of neural-progenitor-cell division. *J Cell Sci.* (2008) 121:2783–93. doi: 10.1242/jcs.023465

76. Wang X, Tsai J-W, LaMonica B, Kriegstein AR. A new subtype of progenitor cell in the mouse embryonic neocortex. *Nat Neurosci.* (2011) 14:555–61. doi: 10.1038/nn.2807

77. Di Lullo E, Kriegstein AR. The use of brain organoids to investigate neural development and disease. *Nat Rev Neurosci.* (2017) 18:573–84. doi: 10.1038/nrn.2017.107

78. Wang H. Modeling Neurological Diseases With Human Brain Organoids. *Front Synaptic Neurosci.* (2018) 10:15. doi: 10.3389/fnsyn.2018.00015

79. Lancaster MA, Knoblich JA. Generation of cerebral organoids from human pluripotent stem cells. *Nat Protoc.* (2014) 9:2329–40. doi: 10.1038/nprot.2014.158

80. Sakaguchi H, Kadoshima T, Soen M, Narii N, Ishida Y, Ogushi M, et al. Generation of functional hippocampal neurons from self-organizing human embryonic stem cell-derived dorsomedial telencephalic tissue. *Nat Commun.* (2015) 6:6896. doi: 10.1038/ncomms9896

81. Kadoshima T, Sakaguchi H, Nakano T, Soen M, Ando S, Irikura M, Sasaki Y. Self-organization of axial polarity, inside-out layer pattern, and species-specific progenitor dynamics in human ES cell-derived neocortex. *Proc Natl Acad Sci USA.* (2013) 110:20284–9. doi: 10.1073/pnas.1315710110

82. Jo J, Xiao Y, Sun AX, Cukuroglu E, Tran H-D, Göke J, et al. Midbrain–dopaminergic and neuromelanin-producing neurons. *Cell Stem Cell.* (2017) 20:2329–40. doi: 10.1016/j.stem.2016.07.005

83. Monzel AS, Smits LM, Hemmer K, Hachi S, Moreno EL, van Wuelen T, et al. Derivation of human midbrain-specific organoids from neuroepithelial stem cells. *Stem Cell Reports.* (2017) 8:1144–54. doi: 10.1016/j.stemcr.2017.03.010

84. Qian X, Nguyen HN, Song MM, Hadiano C, Ogden SC, Hammad C, et al. Brain-region-specific organoids using mini-bioreactors for modeling ZIKV exposure. *Cell.* (2016) 165:1238–54. doi: 10.1016/j.cell.2016.04.032

85. Mugguruma K, Nishiyama A, Kawakami H, Hashimoto K, Sasaki Y. Self-organization of polarized cerebellar tissue in 3D culture of human pluripotent stem cells. *Cell Rep.* (2015) 10:337–50. doi: 10.1016/j.celrep.2014.12.051

86. Sugahara K, Kadoshima T, Minaguchi M, Ogushi M, Suen M, Nakano T, et al. Self-formation of adenohypophysis in three-dimensional culture. *Nature.* (2011) 480:570–62. doi: 10.1038/nature10637

87. Pasca AM, Sloan SA, Clarke LE, Tian Y, Makinson CD, Huber N, et al. Functional cortical neurons and astrocytes from human pluripotent stem cells in 3D culture. *Nat Methods.* (2015) 12:671–8. doi: 10.1038/nmeth.3415

88. Quadrato G, Nguyen T, Maccos EJ, Sherwood JL, Min Yang S, Berger DR, et al. Cell diversity and network dynamics in photosensitive human brain organoids. *Acta Oncol.* (2016) 55:751–9. doi: 10.3109/0284186X.2015.1125016

89. Mochiuddin M, Fujita M, Hedlund MA, Petersson G, Ahmed MM. High-dose spatially-fractionated radiation (GRID): a new paradigm in the management of advanced cancers. *Int J Radiat Oncol Biol Phys.* (1999) 45:721–7. doi: 10.1016/S0360-3016(99)00170-4

90. Slatkin DN, Spanne P, Dilmahan FA, Gebbets JO, Lajewicz LA. Subacute neurochemical changes in the human brain following total-body radiation. *Proc Natl Acad Sci USA.* (1995) 92:8733–7. doi: 10.1073/pnas.92.19.8783

91. Dilmahan FA, Zhong Z, Bacarian T, Benveniste H, Romanelli P, Wang R, et al. Interlaced x-ray microplanar beams: a radiosurgery approach with clinical potential. *Proc Natl Acad Sci USA.* (2006) 103:9709–14. doi: 10.1073/pnas.0603567103
112. Meyer J, Eley J, Schmid TE, Combs SE, Dendale R, Prezado Y. Spatially fractionated proton minibeams. *Br J Radiol*. (2019) 92:20180466. doi: 10.1259/bjr.20180466

113. Prezado Y, Jouvion G, Hardy D, Patriarca A, Nauraye C, Berge J, et al. Proton minibeam radiation therapy spares normal rat brain: long-term clinical, radiological and histopathological analysis. *Sci Rep*. (2017) 7:14403. doi: 10.1038/s41598-017-14786-y

114. Henry T, Ureba A, Valdman A, Siegbahn A. Proton grid therapy. *Technol Cancer Res Treat*. (2017) 16:749–57. doi: 10.1177/1533034616681670

115. Lansonneur P, Mammar H, Nauraye C, Patriarca A, Hierso E, Dendale R, et al. First proton minibeam radiation therapy treatment plan evaluation. *Sci Rep*. (2020) 10:7025. doi: 10.1038/s41598-020-63975-9

116. Schneider T, Marzi I, de, Patriarca A, Prezado Y. Advancing proton minibeam radiation therapy: magnetically focussed proton minibeams at a clinical centre. *Sci Rep*. (2020) 10:1384. doi: 10.1038/s41598-020-8052-0

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Schielke, Hartel, Durante, Ritter and Schroeder. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.